Alkermes Completes Avadel Acquisition, Reports Q1 Financials and Pipeline Progress
Alkermes completed its $72 million net revenue acquisition of Avadel Pharmaceuticals in mid-February 2026, gaining access to the sleep medicine market through LUMRYZ. The company reported a 38% year-over-year increase in proprietary product sales and an adjusted EBITDA of $80.3 million despite a GAAP loss. Alkermes is advancing its orexin pipeline with multiple Phase III trials underway.
Tickers: $AVDL
Topics: acquisitions financial_performance pharmaceuticals pipeline_development